BioLife Solutions (BLFS) PT Raised to $64 at Cowen

Cowen analyst Chris Lin raised the price target on BioLife Solutions (NASDAQ: BLFS) to $64.00 (from $50.00) while maintaining an Outperform rating.

The analyst commented, "BLFS delivered a healthy Q2 beat versus Street expectations, driven by strong organic growth (+49% Y/Y) and nearly +200 new customers wins (compared to +80 in Q1 and +213 in FY'20). BLFS lifted its F2021 revenue guidance by +$2M to reflect its recent acquisition of Sexton Biotechnologies, which leaves potential room for a beat-and-raise in Q3, in our view. Outperform; PT to $64."

You May Also Be Interested In

• Securitize Corp (SECZ) PT Raised to $12 at StoneX on 'Innovation Exemption'
• CAVA Group Inc (CAVA) PT Lowered to $80 at JPMorgan, Overweight Rating Maintained
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2